Nova Eye USA Sales Growth Opportunity
Offer Summary
na
g
Nova Eye is seeking to raise approximately A$[8.0] million via the issue of approximately [38.1] million new fully paid ordinary shares ("New Shares")
An institutional Placement to raise up to approximately A$[3.0] million ("Placement")
•
A 1 for [8.0] pro-rata accelerated non-renounceable entitlement offer ("ANREO") to raise approximately A$[5.0] million ("Entitlement Offer") (together,
the "Equity Raising" or "Offer")
The Equity Raising will be conducted at A$[0.210] per New Share representing a:
•
Offer structure and size
•
Offer Price
[23.6]% discount to the last traded price of $[0.275] on [09 February 2024]
•
[24.2]% discount to the 10-day VWAP price of $[0.277]
.
[20.5]% discount to TERP of $[0.264]
Use of Proceeds
Placement and Institutional
Entitlement Offer
Retail Entitlement Offer
Ranking
Bookrunner
Joint Lead Managers
Proceeds from the Equity Raising will be used to advance near-term growth opportunities across Nova Eye's Glaucoma business, including expanding
the geographical presence of iTrack TM Advance sales in the US and Europe, and to broaden the product portfolio in Glaucoma surgical devices.
The Placement and the Institutional component of the Entitlement Offer (Institutional Entitlement Offer) will be conducted by way of a bookbuild process
from [9am] [Monday, 12 February 2024] to [12pm] [Tuesday, 13 February 2024].
Entitlements under the Institutional Entitlement Offer that are not taken-up, entitlements of ineligible institutional shareholders and ineligible retail
shareholders under the Entitlement Offer will also be sold in the bookbuild process.
The Record date for the Retail component of the Entitlement Offer ("Retail Entitlement Offer") is 7.00pm [Wednesday, 14 February 2024].
The Retail Entitlement Offer will open on [Monday, 19 February 2024] and close on [Friday, 08 March 2024]
Each New Share issued under the Equity Raising will rank equally with existing fully paid ordinary shares on issue
E&P Corporate Advisory
E&P Corporate Advisory, MST Financial, Taylor Collison
nova-eye.com | 21View entire presentation